← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
TruBridge preserved positive profit and strong free cash flow on modest growth, but unresolved material weaknesses and corrected prior statements limit confidence in the reported stability.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 1.4%OK
- Profitability — The company moved from a net loss of $20.945M to net income of $4.354MOK
- Cash flow — Free cash flow grew 20.8% to $35.645M from $29.498MOK
- Margins — Operating margin expanded 415 bps to 6.01%OK
- Accounting — Cash-generative healthcare technology with control gapsNote
- Insiders — 14 purchases and 0 salesOK
Business
TruBridge provides revenue-cycle management, electronic health records and business-management technology to community hospitals and healthcare providers.
Where the revenue comes from
Fiscal 2025, as TruBridge, Inc. reports it. History and quarterly detail are in the app.
- Financial Health$221.7M
- Patient Care$125.2M
Leadership changes
From TruBridge, Inc.'s own filings, the day they're filed.
- David A. Dye · Chief Operating Officer · departureeff. 2024-12-31
- Denise W. Warren · Directors · departureeff. 2024-11-15
- Charles P. Huffman · Directors · departureeff. 2024-02-05
Latest filings
- 8-K · Company announcement2026-07-09
- 8-K · Company announcement2026-07-07
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about TruBridge, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.